中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2014年
3期
259-261
,共3页
李军%张西志%花威%张先稳%汤晓斌%陈达
李軍%張西誌%花威%張先穩%湯曉斌%陳達
리군%장서지%화위%장선은%탕효빈%진체
胸段食管肿瘤/容积调强弧形治疗%剂量体积直方图%剂量学验证
胸段食管腫瘤/容積調彊弧形治療%劑量體積直方圖%劑量學驗證
흉단식관종류/용적조강호형치료%제량체적직방도%제량학험증
Chest esophageal neoplasms/volume modulated arc therapy%Dose volume histogram%Dosimetry verification
目的 探讨VMAT计划在胸段食管癌放疗中的适应性.方法 应用0.6 cm3指形电离室和COMPASS三维剂量验证系统分别对10例胸上段、10例胸中段食管癌的VMAT计划进行绝对剂量和相对剂量的验证.应用DVH比较靶区、肺、心脏和脊髓受照剂量和体积差异,并分析GTV、CTV、PTV和OAR的γ通过率.结果 胸上、中段食管癌的等中心处绝对剂量精确度均≥99％,GTV、PTV和OAR的γ通过率均≥97％.胸上段食管癌GTV、CTV、PTV的D95％、Dmean的验证差异均≤3％,脊髓D1％差异为2.21％,左肺和右肺的V5～ V30、Dmean的差异≤2％.胸中段食管癌的GTV、CTV、PTV和OAR的D95％、Dmean的验证差异≤2％,脊髓D1％差异为2.04％.左肺和右肺的V5～ V30以V10为界差异呈逐渐增大的趋势,处于1.5％以内.心脏Dmean的差异为2.68％.结论 VMAT技术在胸段食管癌放疗中是适用的.
目的 探討VMAT計劃在胸段食管癌放療中的適應性.方法 應用0.6 cm3指形電離室和COMPASS三維劑量驗證繫統分彆對10例胸上段、10例胸中段食管癌的VMAT計劃進行絕對劑量和相對劑量的驗證.應用DVH比較靶區、肺、心髒和脊髓受照劑量和體積差異,併分析GTV、CTV、PTV和OAR的γ通過率.結果 胸上、中段食管癌的等中心處絕對劑量精確度均≥99％,GTV、PTV和OAR的γ通過率均≥97％.胸上段食管癌GTV、CTV、PTV的D95％、Dmean的驗證差異均≤3％,脊髓D1％差異為2.21％,左肺和右肺的V5～ V30、Dmean的差異≤2％.胸中段食管癌的GTV、CTV、PTV和OAR的D95％、Dmean的驗證差異≤2％,脊髓D1％差異為2.04％.左肺和右肺的V5～ V30以V10為界差異呈逐漸增大的趨勢,處于1.5％以內.心髒Dmean的差異為2.68％.結論 VMAT技術在胸段食管癌放療中是適用的.
목적 탐토VMAT계화재흉단식관암방료중적괄응성.방법 응용0.6 cm3지형전리실화COMPASS삼유제량험증계통분별대10례흉상단、10례흉중단식관암적VMAT계화진행절대제량화상대제량적험증.응용DVH비교파구、폐、심장화척수수조제량화체적차이,병분석GTV、CTV、PTV화OAR적γ통과솔.결과 흉상、중단식관암적등중심처절대제량정학도균≥99％,GTV、PTV화OAR적γ통과솔균≥97％.흉상단식관암GTV、CTV、PTV적D95％、Dmean적험증차이균≤3％,척수D1％차이위2.21％,좌폐화우폐적V5～ V30、Dmean적차이≤2％.흉중단식관암적GTV、CTV、PTV화OAR적D95％、Dmean적험증차이≤2％,척수D1％차이위2.04％.좌폐화우폐적V5～ V30이V10위계차이정축점증대적추세,처우1.5％이내.심장Dmean적차이위2.68％.결론 VMAT기술재흉단식관암방료중시괄용적.
Objective To study the dosimetry characteristics of VMAT plan in the esophageal carcinoma radiotherapy.Methods Application of 0.6 cm3 ionization chamber and COMPASS threedimensional dose verification system,20 cases of upper and middle chest esophageal carcinoma on the VMAT plans for absolute dose and relative dose verification.Dose volume histogram (DVH) comparison treatment target,lungs,heart,and differences in the spinal cord irradiation dose and volume,and analyses γpass rate of GTV,CTV,PTV and organs at risks.Results The center dose of upper and middle chest esophageal carcinoma accurate rates were above 99％.Thoracic segment esophageal:GTV,PTV and organs at risks of γ pass rate above 97％.D95％ and Dmean of GTV,CTV and PTV were relatively undervalued within 3％.D1％ of spinal cord is 2.21％ overvalued.Left and right pulmonary V5 were slightly overvalued by about 0.5％,V10-D30,Dmean undervalued within 2％.In period of middle chest esophageal carcinoma:the gamma passed rate of GTV,CTV,PTV and organs at risks of above 97％,GTV,CTV,PTV D95％,Dmean were relatively undervalued within 2％.Spinal cord D1％ is 2.04％ overvalued.Left and right pulmonary V5-D30 to V10 as a trend of gradually to be underestimated,at 1.5％.Heart Dmean was undervalued by 2.68％.Conclusion VMAT technology is applicable in the chest esophageal carcinoma radiotherapy.
